Trouble Viewing This Email: Click Here
 
 

April 4, 2023

FOUNDING MEMBER OF

 
Unlocking a New Era of Healing: Protein Engineering’s Transformative Impact on Therapeutics - BioTalk Welcomes Dr. Luis Alvarez of Frederick MD’s Theradaptive
 

How will protein engineering unleash a new era of therapeutic possibilities for BioHealth and the BioHealth Capital Region? Join us on this episode of BioTalk with Rich Bendis as Rich chats with Dr. Luis Alvarez, Founder & CEO of Theradaptive, who is at the forefront of protein engineering technology. Learn about Theradaptive’s ingenious approach to overcoming the challenges of naturally occurring proteins, elevating the efficacy and safety of therapeutics through precision-targeted delivery, and mitigating off-target side effects. From spinal fusion and orthopedics to soft tissue repair and targeted chemotherapeutics, Theradaptive’s breakthrough technology is set to transform the lives of millions grappling with debilitating conditions linked to loss of tissue function. Be part of the conversation that’s unlocking a world of untapped potential in the convergence of protein engineering and therapeutic discovery. Listen now here or via your favorite podcasting platforms:

 

 

 

Read More

 
 
Gaithersburg’s Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
 

MARCH 28, 2023 - GAITHERSBURG, Md., (BUSINESS WIRE) -- Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment will be used to advance and accelerate lead candidate JK07, including the planned initiation of the first Phase 2 study in HFrEF, the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction (HFpEF), and the launch of the Company’s first neurology clinical trial with JK07. The financing will also support the ongoing Phase 1/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1/2 study.

Read More

 
 
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology
 

Leiden, the Netherlands , March 28, 2023 / B3C newswire / -- MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company. The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

 

Read More

 
 
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions' NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
 
  • NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access
  • Expected over-the-counter availability is anticipated by late summer of this year

GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering NARCAN® Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

Read More

 
 
Medcura Advancing Hemostat Innovation and Fostering Growth in the BioHealth Capital Region
 

April 3, 2023 - Medcura, Inc., a life science and medical device company based in Riverdale, MD, is experiencing substantial growth in the BioHealth Capital Region. The company has developed a cutting-edge proprietary biosurgical technology demonstrating the rapid arrest of difficult-to-control surgical bleeding. This innovative technology offers the industry-best highly disruptive economics and has been tested in numerous challenging pre-clinical models. In addition to its versatility, the platform can be expanded into highly differentiated product solutions, as seen in Medcura's emerging surgical and recently commercialized consumer product applications. Notably, the company's products have garnered recognition for quickly stopping bleeding using naturally abundant and highly economical ingredients.

Read More

 
 
TEDCO’s Maryland Innovation Initiative Announced Recent Investments
 

$600,000 invested into 3 new ventures and $1.6Million awarded to 12 project grants

COLUMBIA, Md. (March 29, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent round of funding through the Maryland Innovation Initiative (MII).

Established in 2012, the MII program was created as a partnership between the State of Maryland and five Maryland academic research institutions: Johns Hopkins University; Morgan State University; University of Maryland, Baltimore; University of Maryland, Baltimore County; and University of Maryland, College Park. The program’s mission is to accelerate and support the commercialization of promising technologies from bench to market through investments in innovation, entrepreneurship and venture creation. 

Read More

 
 
Virginia Tech Corporate Research Center Announces First Companies Selected for JLABS Virtual Residency
 

BLACKSBURG, Va. (March 28, 2023) – The Virginia Tech Corporate Research Center (VTCRC) announced today that three companies have been selected to join Johnson & Johnson Innovation – JLABS (JLABS). Under a collaboration between VTCRC and Johnson & Johnson Innovation, LLC, established to support innovators in the Blacksburg-Roanoke region with the aim to accelerate emerging biotech and life science startups, the selected companies will have full access to JLABS programming, resources, and mentorship from experts across The Johnson & Johnson Family of Companies virtually.

Acomhal Research, Qentoros, and The Tiny Cargo Company will benefit from the JLABS global life science network and industry connections, along with access privileges to the JLABS @ Washington, DC site, while keeping their businesses located in the region.

Read More

 

 
The National Cancer Plan: An Ambitious Mission to End Cancer as We Know It
 

April 3, 2023 - The battle against Cancer has long been a collective effort, with advances in treatment and prevention made possible through the dedicated work of researchers, caregivers, advocates, and the investment of federal, state, and local governments, as well as private investment. Building on the progress made thus far, the National Cancer Plan represents a bold and ambitious framework to end Cancer as we know it. The National Cancer Plan has been developed to coordinate a comprehensive national response to achieving the goals of the Cancer Moonshot initiative, led by President Biden and First Lady Biden, and to deliver better cancer outcomes to all people​.

Image: https://twitter.com/theNCI/status/1642905180596498433/photo/1

Read More

 
 
From Serbia and China to College Park - Maryland Today
 

When husband and wife Zairen Sun Ph.D. ’98 and Beibei Li Ph.D. ’98 arrived in College Park from China in 1992, they had little understanding of their new country or its traditions or practices. What they did have was a mentor at the University of Maryland who knew what it was like to be an immigrant to the U.S.—and who could empathize with the process of adjusting to a very different way of doing things.

Read More

 
In groundbreaking research, Tel Aviv U team records plants 'talking' for first time | The Times of Israel
 

It has been known for some time that plants communicate with one another, but Israeli scientists now say they’ve identified “words,” and have found that different species speak in different “languages,” according to a groundbreaking new study published Thursday in the prestigious scientific journal Cell.

Scientists already know that plants communicate in a variety of ways when they are stressed. They might change physically (by wilting or changing leaf color), become bitter to the taste (to deter herbivores), or emit smells (volatile organic compounds) to tell other members of the family that they are under attack, for example by insects.

Image: Tomatoes were among the plants tested for sound by Tel Aviv University researchers. (David Besa, CC BY 2.0, Wikimedia Commons)

Read More

 
The AI genie is out of the bottle: Should it be crammed back inside?
 

By Tom Still

MADISON, Wis. -- Society has been here many times before. A little more than 200 years ago, a group of English textile workers called the Luddites took to destroying mill machinery -- not because they were inherently anti-technology -- but mainly to protest labor conditions at the time. The movement faded in a few years and the textile industry continued down an inevitable road to automation.

The history of technology reveals many such examples of innovation being met with suspicion and worries that mankind would lose its moral compass. From Gutenberg’s printing press to the dawn of the computer age, people have fretted that new ways and machines would erode the ability of people to discern good from bad while dangerously accelerating change.

Read More

 
UMD I-Corps: Upcoming Workshop Dates
 

The regional UMD I-Corps Customer Discovery Workshops introduce teams and individuals with innovations to the concepts of business models and customer discovery.

UMD offers several live (over Zoom), instructor-led I-Corps workshops each year. You may only join these cohorts with instructor approval upon completing the I-Corps Prerequisite, a self-paced, online course.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright  BioHealth Innovation 2023
All Rights Reserved.